In the last year, multiple insiders have substantially increased their holdings of Liquidia Corporation ( NASDAQ:LQDA...

MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference being held November 16-19, 2021 . The fireside chat will be available to registered participants on-demand beginning at 8:00 a.m. GMT on November 18, 2021. A webcast of the event will be available on th

Russell Schundler, Insider at Liquidia (NASDAQ:LQDA), made a large insider buy on November 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Schundler purchased 117,908 shares of Liquidia at at prices ranging from $4.18 to $4.28. The total transaction amounted to $496,834. Following the transaction, Schundler now owns 235,088 shares of the company, worth $1,123,720. Liquidia shares are trading up 13.0% at $

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Calithera Biosciences The Trade: Calithera Biosciences, Inc. (NASDAQ: CALA) Director Jonathan G Drachman acquired a total

The FDA has granted tentative approval of a Morrisville-based drugmaker's treatment for pulmonary arterial hypertension, but a lawsuit is keeping the company from marketing the drug.

The FDA has granted tentative approval to Liquidia Corporation's (NASDAQ: LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that Yutrepia has met all regulatory standards for quality, safety, and efficacy required for approval in the U.S. Due to a regulatory stay according to the Drug Price Competition and Pate

First dry-powder formulation of treprostinil to meet criteria required for FDA approvalFinal FDA approval may occur in October 2022 or earlier upon resolution of on-going litigationConference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time MORRISVILLE, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previou